期刊
MELANOMA RESEARCH
卷 15, 期 4, 页码 283-285出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00008390-200508000-00008
关键词
chemotherapy; c-kit; immunohistochemistry; melanoma
In order to determine whether imatinib mesylate (Gleevec), a tyrosine kinase inhibitor that binds the CD-117 (c-kit) receptor, may be of value in the treatment of malignant melanoma, an immunohistochemical analysis of 40 cases of primary and metastatic melanoma was undertaken. Thirty-five of the 40 cases showed 1 + or stronger labelling for CD-117 (up to a maximum of 4 +). Three patients with neoplasms showing 4 + staining were selected for imatinib therapy. None responded. c-kit (CD-117) expression in melanoma appears to be common; however, the value of imatinib therapy remains to be proven.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据